RxDoctor Payments Data

Daniel Piazza, DO

Family Medicine · Texas City, TXNPI 1427042431

Payments from drug & device makers

$744in general payments, 2019–2025

Across 38 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$369
  • GSK$125
  • Esperion Therapeutics, Inc.$41
  • Inspire Medical Systems, Inc.$36
  • Lilly USA, LLC$32
  • Astellas Pharma US Inc$28
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$69493%
  • Other$507%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$744 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$124,047
Medicare patients
324
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$132,100
FarxigaDapagliflozin Propanediol99$98,195
MounjaroTirzepatide49$76,001
EliquisApixaban73$64,798
JardianceEmpagliflozin70$62,125
JanuviaSitagliptin Phosphate57$58,287
TrulicityDulaglutide40$52,943
RybelsusSemaglutide27$48,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,857
Tresiba Flextouch U-200Insulin Degludec33$39,643
JanumetSitagliptin Phos/Metformin Hcl29$24,282
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$23,532
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$21,185
Soliqua 100-33Insulin Glargine/Lixisenatide23$15,213
EntrestoSacubitril/Valsartan14$12,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$32$128,94489 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$21$94,544109 claims
Boehringer IngelheimJardiance$21$62,12570 claims
GSKTrelegy Ellipta, Breo Ellipta$125$48,86855 claims
AbbVieArmour Thyroid$16$3,61645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →